BioCentury
ARTICLE | Company News

BioMarin tops 1Q17 estimates

May 4, 2017 11:34 PM UTC

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported 1Q17 revenues that beat analyst expectations and a narrower-than-expected loss, driven by growth in sales of rare disease treatments Vimizim elosulfase alfa and Kuvan sapropterin.

The company reported $304 million in quarterly revenue, up 28% from 1Q16 and beating a consensus estimate of $289 million. Sales of Vimizim were $106 million, up 45% year-over-year and ahead of a $96.6 million consensus, while revenue from Kuvan increased 19% to $92 million, shy of a $93.6 million estimate. The company reported a non-GAAP loss of $0.09 per share, narrower than its $0.51 loss in 1Q16 and beating a consensus estimate of a $0.29 loss...

BCIQ Company Profiles

BioMarin Pharmaceutical Inc.